Ogalvibart
Modify Date: 2024-02-04 16:27:07
Ogalvibart structure
|
Common Name | Ogalvibart | ||
|---|---|---|---|---|
| CAS Number | 2599039-60-6 | Molecular Weight | N/A | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | N/A | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of OgalvibartOgalvibart (C-135-LS) is a humanized anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model[1]. |
| Name | Ogalvibart |
|---|
| Description | Ogalvibart (C-135-LS) is a humanized anti-SARS-CoV-2 monoclonal antibody (IgG1 type). Ogalvibart binds to the spike (S) glycoprotein receptor-binding domain (RBD) of SARS-CoV-2. Ogalvibart in combination with C144LS (1:1 ratio) shows good preventive activity and can effectively block the development of COVID19 in a rhesus monkey disease model[1]. |
|---|---|
| Related Catalog | |
| Target |
SARS-CoV-2[1]. |
| In Vivo | Ogalvibart (C-135-LS; 10 mg/kg; 感染前 75 天给药) 联合 10 mg/kg 的 C144LS 时，能有效阻断恒河猴疾病模型中 COVID19 的发展[1]。 Animal Model: Rhesus macaques (3-11 years old)[1]. Dosage: 10 mg/kg (in combination with 10 mg.kg C144LS) Administration: 75 days before infection Result: Protected a subset of animals whose infectious challenge was 75 days post administration from disease. |
| References |
| No Any Chemical & Physical Properties |